Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug Development
Alzheimer's disease (AD) is still an incurable neurodegenerative disease that causes dementia. AD changes the brain function that, over time, impairs memory and diminishes judgment and reasoning ability. Pathophysiology of AD is complex. Till now the cause of AD remains unknown, but risk factor...
Saved in:
Main Authors: | Sharmin Reza Chowdhury (Author), Fangzhou Xie (Author), Jinxin Gu (Author), Lei Fu (Author) |
---|---|
Format: | Book |
Published: |
Georg Thieme Verlag KG,
2019-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novel harmine derivatives as potent acetylcholinesterase and amyloid beta aggregation dual inhibitors for management of Alzheimer's disease
by: Hongtao Du, et al.
Published: (2023) -
Amyloid-beta clearance in Alzheimer's disease
by: Robert Marr
Published: (2015) -
Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease
by: Serena Vittorio, et al.
Published: (2020) -
Dual-target ligand discovery for Alzheimer's disease: triphenylphosphoranylidene derivatives as inhibitors of acetylcholinesterase and β-amyloid aggregation
by: Marwa El-Hussieny, et al.
Published: (2023) -
Amyloid-beta clearance in Alzheimer's disease: Does exercise play a role?
by: Reza Gharakhanlou, et al.
Published: (2020)